Investigation of the use of miRNA223 as a biomarker in glioma tumors

The purpose of this study is to determine of the use of miRNA223 as a biomarker in glioma tumors. The expression of several microRNAs in glioma tumors has been studied. miRNA223 has been studied in several forms of cancer. This is the first study in literature to investigate the expression level of miRNA223 in patients having glioma at the Turkish population. This study demonstrates the role of possible biomarkers in the expression analysis of miRNA223 in glioma tumors. The blood samples used in this thesis study are previously taken samples and present at the Molecular Medicine Laboratory of Yeditepe University. Yeditepe University Non-Interventional Clinical Research Ethics Committee approval is obtained prior to the study. Blood samples are obtained from the laboratory freezer which were priorly obtained from 35 patients who have referred to Yeditepe University Hospital having glial tumors. Blood samples from 30 healthy subjects are used as a control group. Depending on the location of the tumor, 3 different serum chambers were constructed from patient sera. A serum pool was created from the control structures. Qiagen's miRNeasy Serum/Plasma Kit (Cat. No. / ID: 217184) is used to practice miRNA isolation. Subsequently the cDNA is converted by conventional PCR, using the miRCURY LNA RNA miRCURY LNA RT Kit (Cat. No./ID: 339340 - Qiagen). A fluorometer is used to measure cDNA levels. Dilutions of the samples were made. To detect miRNA expression levels, expression analysis was performed by PCR method in Rotor Gene (Rotor-Gene Q –Qiagen) using miRCURY LNA SYBR Green PCR Kit (Cat. No. / ID: 339346). Real-Time Polymerase Chain Reaction is used to detect miRNA expression levels (RT-PCR). SPSS ver. 23.0 is used for statistical analysis (SPSS Inc, Chicago, IL, USA). ROC curve analysis has been done. The p value is set to 0.05 for statistically significant results.